GSK's Hepatitis B Candidate Secures FDA Priority Review, Breakthrough Designation
Event summary
- The U.S. FDA has accepted a New Drug Application (NDA) for bepirovirsen, a GSK-developed antisense oligonucleotide (ASO) for chronic hepatitis B (CHB), for Priority Review.
- Bepirovirsen has also been granted Breakthrough Therapy Designation by the FDA, setting a PDUFA target action date of October 26, 2026.
- Phase 3 trials (B-Well 1 and B-Well 2) demonstrated statistically significant and clinically meaningful functional cure rates with bepirovirsen plus standard of care.
- Ionis Pharmaceuticals licensed bepirovirsen to GSK in 2019, receiving upfront and milestone payments, with tiered royalties on net sales.
- Regulatory reviews are also underway with the EMA, NMPA, and MHLW, with similar designations secured in China and Japan.
The big picture
Chronic hepatitis B affects over 250 million people globally, representing a significant unmet medical need. Current treatments offer limited functional cure rates, creating an opportunity for bepirovirsen to disrupt the market. GSK's investment in Ionis's ASO technology underscores the growing interest in RNA-targeted therapies for chronic diseases, but the high price point of such therapies could limit accessibility.
What we're watching
- Regulatory Risk
- The October 2026 PDUFA date introduces regulatory risk; a rejection or significant delay would impact both GSK and Ionis's revenue projections and stock performance.
- Market Adoption
- The success of bepirovirsen will depend on its ability to displace existing nucleoside analogues and convince physicians to adopt a novel treatment approach, potentially facing reimbursement hurdles.
- Clinical Durability
- Long-term data on the durability of the functional cure achieved with bepirovirsen will be critical to assess its true value proposition and potential for sustained market adoption.
Related topics